Alcohol intake and risk of rosacea in US women - 14/12/17
Abstract |
Background |
The epidemiologic association between alcohol and rosacea is unclear and inconsistent based on the previous cross-sectional or case-control studies.
Objective |
We conducted a cohort study to determine the association between alcohol intake and the risk of rosacea in women.
Methods |
A total of 82,737 women were included from the Nurses' Health Study II (1991-2005). Information on alcohol intake was collected every 4 years during follow-up. Information on history of clinician-diagnosed rosacea and year of diagnosis was collected in 2005.
Results |
Over 14 years of follow-up, we identified 4945 cases of rosacea. Compared with never drinkers, increased alcohol intake was associated with a significantly increased risk of rosacea (Ptrend <.0001). The multivariate-adjusted hazard ratios (HRs) and confidence intervals (CIs) were 1.12 (95% CI 1.05-1.20) for alcohol intake of 1-4 g/day and 1.53 (1.26-1.84) for ≥30 g/day. The associations remained consistent across categories of smoking status. Further examination of types of alcoholic beverage consumed revealed that white wine (Ptrend <.0001) and liquor intake (Ptrend = .0006) were significantly associated with a higher risk of rosacea.
Limitations |
This was an epidemiologic study without examination into etiologic mechanisms.
Conclusions |
Alcohol intake was significantly associated with an increased risk of rosacea in women.
Le texte complet de cet article est disponible en PDF.Key words : alcohol intake, cohort studies, dose-response relationship, epidemiology, rosacea, smoking
Abbreviations used : CI, HR, NHS II
Plan
| Funding sources: This work was supported by the Department of Dermatology, Warren Alpert Medical School of Brown University and the Nurses' Health Study II grant (UM1 CA176726). Dr Li was supported by the Research Grant of National Rosacea Society and the Research Career Development Award of Dermatology Foundation. |
|
| Conflicts of interest: Dr Drucker has received honoraria from Astellas Canada for speaking and serves as an investigator (with no financial compensation) for Sanofi and Regeneron. The other authors declare no conflicts of interest. |
|
| Reprints not available from the authors. |
Vol 76 - N° 6
P. 1061 - juin 2017 Retour au numéro
Article précédent
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
- Brooke Rothstein, Deep Joshipura, Ami Saraiya, Rana Abdat, Huda Ashkar, Yana Turkowski, Vaneeta Sheth, Victor Huang, Shiu Chung Au, Courtney Kachuk, Nicole Dumont, Alice B. Gottlieb, David Rosmarin
- Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis
- Yu-Chen Huang, Ying-Chih Cheng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?